Immunome (IMNM) Director Isaac Barchas Sells Shares

What Happened
Isaac Barchas, a director of Immunome, sold a total of 36,088 shares of IMNM in two open-market transactions: 20,840 shares on 2026-08-06 for $26.06/share ($543,090) and 15,248 shares on 2026-08-07 for $26.06/share ($397,363). The combined proceeds were approximately $940,453. These were sales (not purchases) executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction dates and prices:
  • 2026-08-06: 20,840 shares sold at a weighted average of $26.06 (total $543,090).
  • 2026-08-07: 15,248 shares sold at a weighted average of $26.06 (total $397,363).
• Total sold: 36,088 shares for ~$940,453; weighted average price reported $26.06.
• Reported price ranges: $26.00 to $26.3318 (per filing footnote); another footnote lists $26.00 to $26.25. Full per-price detail is available upon request.
• These sales occurred automatically pursuant to a Rule 10b5-1 plan adopted by ABHMC II LLC on March 31, 2026.
• Ownership/beneficial interest note: ABHMC II LLC owns the shares; Barchas is the managing member and has power of attorney over those shares and disclaims beneficial ownership except to the extent of any pecuniary interest.
• Filing timeliness: Form 4 filed 2026-08-10; the filing appears timely relative to the reported trade dates.

Context
Sales executed under a 10b5-1 plan are pre-arranged and often automatic, which means they may not reflect the director’s contemporaneous view of the company. The filing indicates institutional ownership (ABHMC II LLC) with Barchas acting in a managerial/agency capacity rather than necessarily owning the shares outright.